Survey by the French Medicine Agency (ANSM) of the imaging protocol, detection rate, and safety of Ga-PSMA-11 PET/CT in the biochemical recurrence of prostate cancer in case of negative or equivocal F-fluorocholine PET/CT: 1084 examinations.

Introduction: Despite growing evidence of a superior diagnostic performance of Ga-PSMA-11 over F-fluorocholine (FCH) PET/CT, the number of PET/CT centres able to label on site with gallium-68 is still currently limited. Therefore, patients with biochemical recurrence (BCR) of prostate cancer frequently undergo FCH as the 1st-line PET/CT. Actually, the positivity rate (PR) of a second-line PSMA-11 PET/CT in case of negative FCH PET/CT has only been reported in few short series, in a total of 185 patients.